Fundz

BIO-key International

HOLMDEL, New Jersey, United States · Biometrics, Cyber Security, Information Technology

BIO-key has over two decades of expertise in providing authentication technology for thousands of organizations and millions of users and is revolutionizing authentication with biometric-centric, multi-factor identity and access management (IAM) solutions, including its PortalGuard IAM solution, that provides convenient and secure access to devices, information, applications, and high-value transa

Key facts

Headquarters
HOLMDEL, New Jersey, United States
Employees
Unknown
Industries
Biometrics, Cyber Security, Information Technology
Status
Public (BKYI)
Website
www.bio-key.com
LinkedIn
Company page

Recent activity at BIO-key International

  • : SEC 8-K (8.01):
  • : SEC 8-K (1.01): On September 29, 2026, BIO-key International, Inc. entered into four separate Exchange Agreements with Streeterville Capital, LLC. This involved the partitioning of a previously issued Secured Promissory Note totaling $1,130,000 into four new Promissory Notes with principal amounts of $68,315.80, $116,000, $117,000, and $115,000. The outstanding balance of the Original Note was reduced by $416,315.80, effectively paying it off. Additionally, the Company exchanged these Partitioned Notes for a total of 247,805 shares of its Common Stock, thereby impacting its equity structure and alleviating debt obligations.
  • : SEC 8-K (8.01):
  • : SEC 8-K (1.01): On August 10, 2026, BIO-key International, Inc. entered into a Warrant Exercise Agreement with an institutional investor to exercise 618,334 outstanding warrants originally issued on October 28, 2025. The exercise price was reduced from $10.20 to $4.06 per share, and the investor received new unregistered warrants for 1,236,668 shares at the same exercise price, with ownership capped at 4.99% of the company's total stock. The transaction generated approximately $2.51 million in gross proceeds for the company, intended for working capital and corporate purposes. The closing occurred on August 11, 2026, and is contingent upon obtaining stockholder approval within the next 120 days, with meetings scheduled every 90 days thereafter if necessary.
  • : SEC 8-K (2.02): On August 13, 2026, BIO-key International, Inc. announced its financial results for the second quarter of 2026. The press release detailed key financial metrics, including revenue and earnings, which are critical for investors evaluating the company's performance. This filing includes the press release attached as Exhibit 99, indicating the company's ongoing operations and potential growth trajectory. The announcement date of August 13, 2026, reflects the timely nature of this financial update, which is crucial for market participants.
  • : SEC 8-K (1.01): On August 10, 2026, BIO-key International, Inc. entered into a Warrant Exercise Agreement with an institutional investor to exercise 618,334 existing warrants for its common stock, reducing the exercise price from $10.20 to $4.06 per share. In exchange for exercising these existing warrants, the investor received new unregistered warrants for an additional 1,236,668 shares, also priced at $4.06 per share. This transaction reflects a strategic adjustment in the financial terms to encourage warrant exercise and enhance liquidity for the company, impacting its capitalization structure significantly.
  • : SEC 8-K (7.01): On July 7, 2026, BIO-key International, Inc. announced via a press release that the trading of its common stock has been reinstated on the Nasdaq Capital Market. This reinstatement is significant for the company as it allows for renewed trading activity and potentially increased investor interest, especially after any prior cessation of trading. The press release is included as Exhibit 99.1 in the filing, emphasizing the importance of this regulatory milestone for the company’s market presence. This positive development is particularly timely given the recent challenges faced by the company, allowing them to engage more actively with investors and stakeholders.
  • : SEC 8-K (7.01): On July 7, 2026, BIO-key International, Inc. announced the reinstatement of trading of its common stock on the Nasdaq Capital Market. This follows a period of suspension, and the reinstatement is expected to enhance liquidity and improve capital-raising opportunities for the company. The press release outlining this significant development is attached as Exhibit 99.1, indicating the timely resolution of trading status issues that potentially affected investor confidence. The company is now poised to engage more actively with investors and the market following the reinstatement.
  • : SEC 8-K (7.01): On June 10, 2026, BIO-KEY INTERNATIONAL, INC. issued a press release related to the matters described in Item 3.01 of the Form 8-K. This disclosure provides information that is significant for investors and is not considered 'filed' under various sections of the securities law. The press release is attached as Exhibit 99.1, suggesting that it contains important updates or announcements that the company deems necessary for security holders. This communication may have strategic implications for investors considering the timing and nature of the disclosures made.
  • : SEC 8-K (7.01):

Dates are the day the event happened, taken from the announcement or SEC filing, unless a row says otherwise.

BIO-key International funding history

DateRoundAmount
Dec 2023Seed$548K
Dec 2022Seed$2.2M
Jul 2019Seed$2.6M
May 2017VentureUndisclosed

Leadership

  • Fabian Shin, Director
  • Yan Jianhui, Director
  • Thomas Gilley, Director
  • Pieter Knook, Director
  • Thomas Bush, Director
  • Robert Michel, Director
  • Wong Fong, Director
  • Michael DePasquale, Executive Officer, Director
  • Fong Kwok, Director
  • Thomas III, Director
  • John Schoenherr, Director

Verified email and direct lines for BIO-key International’s decision-makers are on Fundz. See plans or book a 15-minute walkthrough.

Employee benefit plans

BIO-key International files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Companies similar to BIO-key International

  • CardLab Aps · Biometrics, Cyber Security, Information Technology, Security, Software
  • Facia · Biometrics, Cyber Security, Information Technology, Security, Software
  • PIXM Security · Cyber Security, Information Technology, Privacy And Security, Security, Software
  • Eclipse Bancorp · Cyber Security, Information Technology, Other, Security, Software
  • Expel, Inc. · Cyber Security, Information Technology, Other, Privacy And Security, Software

About BIO-key International: questions and answers

What does BIO-key International do?

BIO-key has over two decades of expertise in providing authentication technology for thousands of organizations and millions of users and is revolutionizing authentication with biometric-centric, multi-factor identity and access management (IAM) solutions, including its PortalGuard IAM solution, that provides convenient and secure access to devices, information, applications, and high-value transa

Where is BIO-key International headquartered?

BIO-key International is headquartered in HOLMDEL, New Jersey, United States.

Has BIO-key International raised funding?

Yes. Fundz has recorded 4 funding events for BIO-key International. The most recent, Seed of $548K, was in Dec 2023.

What is the latest news on BIO-key International?

On Oct 27, 2025, SEC 8-K (8.01):

Is BIO-key International a public company?

Yes. BIO-key International is publicly traded under the ticker BKYI.

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches BIO-key International across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.